Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01346033 · ClinicalTrials.gov registry record

Evaluation of SCOUT DS in Subjects With Type 2 Diabetes

A clinical trial, sponsored by VeraLight.

Completed
Registry status
270
Enrollment target

NCT01346033: Completed study, sponsored by VeraLight.

NCT01346033 is a clinical trial that has completed, run by VeraLight. The registered enrollment target is 270 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01346033 has completed, sponsored by VeraLight.

COMPLETED
Registry status
270 participants
Enrollment target

Study Summary

The primary objective of the trial is to collect SCOUT DS and Hemoglobin A1c measurements of subjects who have been diagnosed with Type 2 diabetes.

Primary Outcome

Collect SCOUT DS and Hemoglobin A1c measurements of subjects with Type 2 Diabetes

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2010-10
Est. Completion 2010-10
VeraLight

10 total trials

What the finished NCT01346033 record still lists

NCT01346033 is an observational study that tracks outcomes without assigning an intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01346033 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01346033 about?

NCT01346033 is a clinical study titled "Evaluation of SCOUT DS in Subjects With Type 2 Diabetes". The primary objective of the trial is to collect SCOUT DS and Hemoglobin A1c measurements of subjects who have been diagnosed with Type 2 diabetes.

What is the current status of trial NCT01346033?

This trial is currently completed. The enrollment target is 270 participants. The study started on 2010-10. Estimated completion is 2010-10.

Who is sponsoring clinical trial NCT01346033?

This trial is sponsored by VeraLight, which has 10 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01346033, the US trial registry maintained by the National Library of Medicine. NCT01346033 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.